To begin to address this problem of lack of appropriate mouse models, in this study we showed that the VpR mutant autochthonous mouse ccRCC model is resistant to anti-PD-1 plus anti-CTLA-4 checkpoint therapy, alone or in combination with other agents. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.